Livzon Pharmaceutical Group Inc
SZSE:000513
Livzon Pharmaceutical Group Inc
SZSE:000513
Price:
39.28 CNY
-1.06%
Market Closed
Updated:
May 18, 2024
Balance Sheet
Balance Sheet Decomposition
Livzon Pharmaceutical Group Inc
Livzon Pharmaceutical Group Inc
| Current Assets | 17.3B |
| Cash & Short-Term Investments | 11.4B |
| Receivables | 3.7B |
| Other Current Assets | 2.2B |
| Non-Current Assets | 7.8B |
| Long-Term Investments | 1.7B |
| PP&E | 4.7B |
| Intangibles | 839.1m |
| Other Non-Current Assets | 524.8m |
| Current Liabilities | 8.1B |
| Accounts Payable | 763.8m |
| Accrued Liabilities | 388.2m |
| Short-Term Debt | 2.8B |
| Other Current Liabilities | 4.2B |
| Non-Current Liabilities | 2.9B |
| Long-Term Debt | 1.6B |
| Other Non-Current Liabilities | 1.3B |
Balance Sheet
Livzon Pharmaceutical Group Inc
Livzon Pharmaceutical Group Inc
Currency: CNY
| Dec-2014 | Dec-2015 | Dec-2016 | Dec-2017 | Dec-2018 | Dec-2019 | Dec-2020 | Dec-2021 | Dec-2022 | Dec-2023 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | |||||||||||
| Cash & Cash Equivalents |
716
|
798
|
2 062
|
7 401
|
8 564
|
8 854
|
9 952
|
9 145
|
10 410
|
11 321
|
|
| Cash |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
9 125
|
10 073
|
11 321
|
|
| Cash Equivalents |
716
|
798
|
2 062
|
7 401
|
8 564
|
8 854
|
9 952
|
20
|
338
|
0
|
|
| Short-Term Investments |
6
|
7
|
6
|
19
|
16
|
17
|
26
|
183
|
108
|
82
|
|
| Total Receivables |
1 430
|
1 667
|
2 066
|
2 612
|
2 474
|
2 532
|
2 998
|
3 379
|
4 110
|
3 655
|
|
| Accounts Receivables |
1 073
|
1 256
|
1 464
|
1 357
|
1 382
|
1 472
|
1 743
|
1 952
|
2 415
|
2 116
|
|
| Other Receivables |
357
|
411
|
602
|
1 255
|
1 092
|
1 060
|
1 255
|
1 428
|
1 695
|
1 539
|
|
| Inventory |
847
|
984
|
1 099
|
1 103
|
1 117
|
1 169
|
1 488
|
1 663
|
2 045
|
2 061
|
|
| Other Current Assets |
166
|
122
|
738
|
225
|
301
|
301
|
164
|
302
|
314
|
148
|
|
| Total Current Assets |
3 166
|
3 578
|
5 971
|
11 360
|
12 472
|
12 873
|
14 627
|
14 673
|
16 987
|
17 266
|
|
| PP&E Net |
3 505
|
3 731
|
3 658
|
3 579
|
3 622
|
3 638
|
3 948
|
4 563
|
4 778
|
4 734
|
|
| PP&E Gross |
3 505
|
3 731
|
3 658
|
3 579
|
3 622
|
3 638
|
3 948
|
4 563
|
4 778
|
4 734
|
|
| Accumulated Depreciation |
1 638
|
1 853
|
2 135
|
2 107
|
2 354
|
2 623
|
2 949
|
3 281
|
3 673
|
4 115
|
|
| Intangible Assets |
258
|
273
|
314
|
289
|
325
|
378
|
488
|
835
|
826
|
714
|
|
| Goodwill |
103
|
103
|
103
|
103
|
103
|
103
|
103
|
103
|
103
|
125
|
|
| Note Receivable |
0
|
0
|
0
|
47
|
39
|
39
|
34
|
57
|
3
|
3
|
|
| Long-Term Investments |
179
|
249
|
238
|
276
|
596
|
651
|
988
|
1 695
|
1 738
|
1 681
|
|
| Other Long-Term Assets |
91
|
144
|
246
|
244
|
280
|
294
|
402
|
446
|
432
|
521
|
|
| Other Assets |
103
|
103
|
103
|
103
|
103
|
103
|
103
|
103
|
103
|
125
|
|
| Total Assets |
7 303
N/A
|
8 078
+11%
|
10 529
+30%
|
15 898
+51%
|
17 437
+10%
|
17 976
+3%
|
20 591
+15%
|
22 372
+9%
|
24 868
+11%
|
25 045
+1%
|
|
| Liabilities | |||||||||||
| Accounts Payable |
599
|
637
|
588
|
502
|
636
|
547
|
707
|
791
|
854
|
764
|
|
| Accrued Liabilities |
72
|
83
|
235
|
239
|
300
|
361
|
1 252
|
1 227
|
523
|
388
|
|
| Short-Term Debt |
729
|
549
|
674
|
662
|
2 219
|
2 077
|
2 469
|
3 080
|
2 646
|
2 768
|
|
| Current Portion of Long-Term Debt |
0
|
400
|
0
|
0
|
0
|
0
|
9
|
9
|
10
|
660
|
|
| Other Current Liabilities |
1 269
|
1 486
|
1 814
|
3 008
|
2 215
|
2 308
|
1 646
|
1 819
|
3 363
|
3 508
|
|
| Total Current Liabilities |
2 669
|
3 155
|
3 311
|
4 411
|
5 370
|
5 294
|
6 083
|
6 925
|
7 397
|
8 087
|
|
| Long-Term Debt |
467
|
1
|
1
|
1
|
1
|
0
|
370
|
642
|
1 986
|
1 622
|
|
| Deferred Income Tax |
7
|
12
|
17
|
27
|
54
|
91
|
143
|
157
|
192
|
210
|
|
| Minority Interest |
386
|
464
|
600
|
461
|
1 098
|
1 108
|
1 533
|
1 307
|
1 060
|
724
|
|
| Other Liabilities |
77
|
100
|
95
|
226
|
263
|
317
|
354
|
337
|
357
|
359
|
|
| Total Liabilities |
3 606
N/A
|
3 731
+3%
|
4 023
+8%
|
5 125
+27%
|
6 785
+32%
|
6 810
+0%
|
8 484
+25%
|
9 368
+10%
|
10 992
+17%
|
11 002
+0%
|
|
| Equity | |||||||||||
| Common Stock |
296
|
397
|
426
|
553
|
719
|
935
|
945
|
938
|
936
|
924
|
|
| Retained Earnings |
3 221
|
3 814
|
4 400
|
8 624
|
8 600
|
9 042
|
9 682
|
10 461
|
11 182
|
11 653
|
|
| Additional Paid In Capital |
213
|
396
|
1 820
|
1 715
|
1 362
|
1 163
|
1 560
|
1 629
|
1 627
|
1 322
|
|
| Unrealized Security Profit/Loss |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
143
|
211
|
155
|
|
| Treasury Stock |
0
|
247
|
140
|
67
|
0
|
0
|
250
|
71
|
56
|
0
|
|
| Other Equity |
33
|
13
|
1
|
53
|
29
|
26
|
170
|
96
|
24
|
12
|
|
| Total Equity |
3 697
N/A
|
4 346
+18%
|
6 506
+50%
|
10 773
+66%
|
10 652
-1%
|
11 167
+5%
|
12 107
+8%
|
13 004
+7%
|
13 876
+7%
|
14 042
+1%
|
|
| Total Liabilities & Equity |
7 303
N/A
|
8 078
+11%
|
10 529
+30%
|
15 898
+51%
|
17 437
+10%
|
17 976
+3%
|
20 591
+15%
|
22 372
+9%
|
24 868
+11%
|
25 045
+1%
|
|
| Shares Outstanding | |||||||||||
| Common Shares Outstanding |
845
|
872
|
935
|
935
|
935
|
935
|
939
|
918
|
927
|
924
|
|
Switch to:
Switch to:
See Also
Discover More
You don't have any saved screeners yet
